NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

OSRH

OSR Holdings Inc

Jul 11 • 04:00PM ET

1.18

Dollar change -0.03
Percentage change -2.48	%

Healthcare • Biotechnology • USA • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.00	Insider Own	66.08%	Shs Outstand	19.28M	Perf Week	-12.59%
Market Cap	22.75M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	6.54M	Perf Month	-29.34%
Enterprise Value	82.45M	PEG	-	EPS next Q	-	Inst Own	0.33%	Short Float	1.39%	Perf Quarter	-22.88%
Income	-13.74M	P/S	29.93	EPS this Y	-	Inst Trans	187.85%	Short Ratio	0.66	Perf Half Y	-89.58%
Sales	0.76M	P/B	0.30	EPS next Y	-	ROA	-12.98%	Short Interest	0.09M	Perf YTD	-89.77%
Book/sh	3.93	P/C	14.22	EPS next 5Y	-	ROE	-25.40%	52W High	13.40 -91.19%	Perf Year	-88.74%
Cash/sh	0.08	P/FCF	-	EPS past 3/5Y	-1003.77% -265.93%	ROIC	-18.07%	52W Low	1.02 15.69%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-276.45%	Volatility	11.68% 12.88%	Perf 5Y	-
Dividend TTM	-	EV/Sales	108.49	EPS Y/Y TTM	-12743.04%	Oper. Margin	-787.05%	ATR (14)	0.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.20	Sales Y/Y TTM	-	Profit Margin	-1805.30%	RSI (14)	39.95	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.25	EPS Q/Q	-9662.62%	SMA20	-14.59%	Beta	1.57	Target Price	-
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	-11.06%	Rel Volume	0.85	Prev Close	1.21
Employees	5	LT Debt/Eq	0.00	Earnings	-	SMA200	-81.23%	Avg Volume	137.82K	Price	1.18
IPO	Mar 17, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	117,291	Change	-2.48%

Jul-08-25 10:03AM	OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG (PR Newswire)
May-22-25 07:36AM	OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token (PR Newswire) +5.25%
May-02-25 07:30AM	Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics (PR Newswire)
Apr-09-25 07:54AM	Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology (PR Newswire)
Apr-03-25 07:30AM	OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies (PR Newswire) +68.03%
07:16AM	Loading…
Mar-26-25 07:16AM	Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma (PR Newswire) +136.87%
Mar-25-25 07:00AM	OSR Holdings Appoints Dr. Constance Hfer as Chief Scientific Officer (PR Newswire) -7.51%

OSR Holdings, Inc. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OSRH

OSR Holdings Inc

Upgrade your FINVIZ experience